Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
|
|
- かずただ かたづ
- 5 years ago
- Views:
Transcription
1 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) Staphylococcus aureus 53.0% methicillin S. aureus (MRSA) Staphylococcus epidermidis 65.8% methicillin S. epidermidis (MRSE) MRSA MRSE vancomycin (VCM)
2 432 ( 46 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec quinupristin/dalfopristin (QPR/DPR) MIC 90 2 mg/ml Streptococcus pneumoniae penicillin penicillin S. pneumoniae (gpisp) penicillin S. pneumoniae (gprsp) 87.6% gpisp gprsp ceftriaxone cefpirome cefepime VCM teicoplanin (TEIC) linezolid (LZD) QPR/DPR 1 mg/ml MIC 90 Enterococcus faecalis Enterococcus faecium VCM TEIC MIC 2 mg/ml LZD E. faecalis E. faecium 10.9% 3.5% QPR/DPR E. faecium 24.4% Clostridium difficile VCM MIC 1 mg/ml Peptococcus Bacteroides Prevotella B. fragilis ) MIC (PCs): benzylpenicillin (PCG) ampicillin (ABPC) piperacillin (PIPC) oxacillin (MPIPC) (CEPs): cefazolin (CEZ) cefotiam (CTM) cefmetazole (CMZ) flomoxef (FMOX) ceftriaxone (CTRX) ceftazidime (CAZ) cefotaxime (CTX) cefpirome (CPR) cefozopran (CZOP) cefepime (CFPM) (CBPs): doripenem (DRPM) meropenem (MEPM) imipenem (IPM) panipenem (PAPM) biapenem (BIPM) (GPs): vancomycin (VCM) teicoplanin (TEIC) minocycline (MINO linezolid (LZD) quinupristin/dalfopristin (QPR/DPR) sulfamethoxazole-trimethoprim (ST) arbekacin (ABK) QPR/DPR 3:7 ST 19 : 1 trimethoprim MIC PCs: PCG (U. S. Pharmacopeia (USP) ABPC (USP) CEPs: CMZ (USP)
3 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 47 ) FMOX CTX (USP) CTRX (USP) CAZ (USP) CPR CZOP CFPM (USP) cefoperazone (CPZ USP) sulbactam (SBT USP) latamoxef LMOX CBPs: DRPM MEPM (USP) IPM (USP) PAPM BIPM GPs: VCM clindamycin (CLDM USP fosfomycin FOM Manual of Clinical Microbiology Eighth Edition 14) MIC Clinical and Laboratory Standards Institute (CLSI) 15 17) 3. MIC CLSI 16, 17) 18) Streptococcus cation Mueller- Hinton broth (CAMHB) Streptococcus 5% CAMHB Staphylococcus MPIPC MIC 2%NaCl CAMHB ST MIC 7.5% CAMHB FOM MIC 25 mg/ml glucose-6-phosphate Mueller-Hinton agar 5% hemin 5 mg/ml Vitamin K1 1 mg/ml Brucella agar CLSI 15,17) Streptococcus pneumoniae penicillin (PBP) 4. Polymerase chain reaction (PCR) S. pneumoniae PBP penicillin ver Staphylococcus 1) Staphylococcus aureus 215 methicillin S. aureus (MSSA) methicillin S. aureus (MRSA) 101 (47.0%) 114 (53.0%) Fig MRSA 50 60% 59.0% 29.3% MRSA 2 MSSA MRSA Table 1 2 MSSA CEPs FMOX CEZ CTM MIC 90 1 mg/ml CBPs MEPM MIC mg/ml mg/ml ST CBPs MIC mg/ml VCM TEIC QPR/DPR MIC 90 1 mg/ml LZD MIC 8 mg/ml
4 434 ( 48 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Fig. 1. Incidence of methicillin-resistant Staphylococcus aureus in clinical strains of S. aureus isolated in 1992 to Table 1. Susceptibility distribution of 101 clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA) 1).
5 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 49 ) Table 2. Susceptibility distribution of 114 clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA)*. CLSI 4 mg/ml 84% MINO MIC mg/ml (MIC 8 mg/ml) MIC 16 mg/ml 7 FOM MIC 90 4 mg/ml MIC 64 mg/ml 4 MRSA VCM QPR/DPR ST MIC 90 1 mg/ml TEIC MIC 90 2 mg/ml MSSA LZD MSSA MIC 4 mg/ml 37% ABK MIC 90 4 mg/ml MIC 8 mg/ml 2 b- (BLs) MINO MIC mg/ml 2) Staphylococcus epidermidis 117 methicillin S. epidermidis (MSSE) 40 (34.2%) methicillin S. epidermidis (MRSE) 77 (65.8%) S. aureus Table 3 4 MSSE PCs BLs 2 mg/ ml MIC 90 CBPs MIC mg/ml VCM LZD QPR/DPR MIC 90 2 mg/ml TEIC MIC 90 8 mg/ml (MIC 16 mg/ml) MIC 32 mg/ml 1 MRSA S. aureus ST MSSE MIC 4 mg/ml 6 (15.0%) VCM LZD QPR/DPR MRSE MIC 2 mg/ml TEIC MIC 16 mg/ml 19 (24.7%) MIC mg/ml ST
6 436 ( 50 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 3. Susceptibility distribution of 40 clinical isolates of methicillin-susceptible Staphylococcus epidermidis (MSSE) 1). Table 4. Susceptibility distribution of 77 clinical isolates of methicillin-resistant Staphylococcus epidermidis (MRSE) 1).
7 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 51 ) Table 5. Susceptibility distribution of 37 clinical isolates of Staphylococcus haemolyticus. MRSE 26 (33.8%) MSSE BLs CTM CZOP MIC 90 4 mg/ml 8 mg/ml 16 mg/ml 3) Staphylococcus haemolyticus (89.2%) methicillin (Table 5) VCM LZD QPR/DPR MIC 90 2 mg/ml TEIC 3 (8.1%) ST 11 (29.7%) 4) Staphylococcus saprophyticus 4 CBPs QPR/DPR ST MIC 0.5 mg/ml (Table 6) VCM TEIC LZD MIC 2 mg/ml 5) Staphylococcus lugdunensis 21 methicillin 1 CEPs FMOX methicillin MIC 0.5 mg/ml VCM TEIC LZD QPR/DPR ST MIC 1 mg/ml methicillin CBPs MIC 0.25 mg/ml (Table 7) 6) Staphylococcus capitis 12 6 methicillin 12 VCM TEIC LZD QPR/DPR MIC 2 mg/ml (Table 8) ST mg/ml MIC 8 mg/ml MIC 1 BLs MIC mg/ml
8 438 ( 52 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 6. Susceptibility distribution of 4 clinical isolates of Staphylococcus saprophyticus. Table 7. Susceptibility distribution of 21 clinical isolates of Staphylococcus lugdunensis. 7) coagulase-negative Staphylococcus (CNS) Staphylococcus caprae 10 Staphylococcus warneri 9 Staphylococcus hominis 8 Staphylococcus spp. 4 Table 9
9 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 53 ) Table 8. Susceptibility distribution of 12 clinical isolates of Staphylococcus capitis. Table 9. Susceptibility distribution of 31 clinical isolates of miscellaneous coagulase-negative staphylococci 1) methicillin BLs VCM LZD QPR/DPR MIC 90 1 mg/ml 2 mg/ml 0.5 mg/ml TEIC MIC 90 2 m g/ml MIC 32 mg/ml 1
10 440 ( 54 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 10. Susceptibility distribution of 67 clinical isolates of Streptococcus pyogenes. Table 11. Susceptibility distribution of 71 clinical isolates of Streptococcus agalactiae. ST 6 MIC 90 8 mg/ml 2. Streptococcus 1) Streptococcus pyogenes 67 (Table 10) BLs MIC 0.25 mg/ml 2) Streptococcus agalactiae 71 S. pyogenes (Table 11)
11 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 55 ) Fig. 2. Mutations in penicillin-binding proteins in clinical strains of Streptococcus pneumoniae isolated in 2000, 2002, 2004 and BLs MIC mg/ml MIC 1 mg/ml 1 3) Streptococcus pneumoniae 121 BLs PBP PBP1a PBP2b PBP2x PCR UBUKATA 19) penicillin S. pneumoniae (gpssp) PBP penicillin S. pneumoniae (gpisp) PBP penicillin S. pneumoniae (gprsp) Fig. 2 gpssp gprsp gpisp gprsp 2000 (87.6%) gpssp MIC 90 1 mg/ml (Table 12) gpisp gprsp gpssp BLs CTRX CPR CFPM CBPs 1 mg/ml MIC 90 (Table 13 14) PBP PCG (Table 15) VCM TEIC LZD QPR/DPR PCG PBP mg/ml MIC 90 QPR/DPR MIC 2 mg/ml gpisp gprsp 1 (2%) 2 (4%) 4) Streptococcus mitis group Streptococcus sanguinis group Streptococcus oralis 23 S. mitis 8 S. sanguinis 3 Streptococcus gordonii 3 Streptococcus parasanguinis 1 S. mitis group S. sanguinis group Table 16 CBPs BLs PRSP BLs CBPs MIC mg/ml VCM TEIC LZD MIC mg/ml VCM
12 442 ( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 12. Susceptibility distribution of 15 clinical isolates of penicillin-susceptible Streptococcus pneumoniae (gpssp)*. Table 13. Susceptibility distribution of 55 clinical isolates of penicillin-intermediate Streptococcus pneumoniae (gpisp)*. MIC 0.5 mg/ml QPR/DPR MIC 2 mg/ml 5 (13%) 5) Streptococcus anginosus group S. anginosus 9 Streptococcus constellatus 3 Streptococcus intermedius 1 S. anginosus
13 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 57 ) Table 14. Susceptibility distribution of 51 clinical isolates of penicillin-resistant Streptococcus pneumoniae (gprsp)*. Table 15. Susceptibility distribution of gpssp, gpisp and gprsp. Table 16. Susceptibility distribution of 38 clinical isolates of Streptococcus mitis group and Streptococcus sanguinis group*.
14 444 ( 58 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 17. Susceptibility distribution of 13 clinical isolates of the Streptococcus anginosus group*. group Table 17 BLs CPR CBPs MIC mg/ml VCM TEIC LZD VCM TEIC MIC 1 mg/ml mg/ml QPR/DPR S. pneumoniae S. mitis group S. sanguinis group MIC 2 mg/ml 4 (31%) 3. Enterococcus 1) Enterococcus faecalis E. faecalis 119 CEPs MIC mg/ml PCs CBPs CEPs ABPC IPM MIC 90 2 mg/ml (Table 18) VCM TEIC MIC mg/ml LZD 13 (11%) MIC 90 4 mg/ml 2) Enterococcus faecium E. faecium 86 Table 19 VCM TEIC MIC 90 1 mg/ml LZD 3 (3%) QPR/DPR 21 (24%) 3) Enterococcus avium E. avium 33 ABPC CBPs VCM TEIC MIC 1 m g/ml 0.5 mg/ml (Table 20) LZD 2 (6%) QPR/DPR 28 (85%) 4) Enterococcus raffinosus E. raffinosus 24 ABPC CBPs VCM TEIC MIC
15 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 59 ) Table 18. Susceptibility distribution of 119 clinical isolates of Enterococcus faecalis. Table 19. Susceptibility distribution of 86 clinical isolates of Enterococcus faecium. Table 20. Susceptibility distribution of 33 clinical isolates of Enterococcus avium. 1 mg/ml (Table 21) LZD 4 QPR/DPR 1 5) Enterococcus casseliflavus Enterococcus gallinarum E. casseliflavus 7 ABPC IPM PAPM MIC 2 mg/ml (Table 22) E. gallinarum 6
16 446 ( 60 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 21. Susceptibility distribution of 24 clinical isolates of Enterococcus raffinosus. Table 22. Susceptibility distribution of clinical isolates of Enterococcus casseliflavus and Enterococcus gallinarum. VCM vanc Enterococcus VCM E. gallinarum 3 (50.0%) TEIC MIC 1 mg/ml LZD QPR/DPR Enterococcus
17 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 61 ) Table 23. Susceptibility distribution of 40 clinical isolates of Peptococcaceae*. Table 24. Susceptibility distribution of 28 clinical isolates of Clostridium difficile. 4. 1) Peptococcus Finegoldia magna 14 Schleiferella asaccharolytica 9 Micromonas micros 8 Peptostreptococcus anaerobius 4 Anaerococcus vaginalis 4 Anaerococcus hydrogenalis 1 Table 23 Peptococcus CMZ FMOX CBPs VCM MIC mg/ml CLDM MIC 64 mg/ml 5 2) Clostridium difficile C. difficile 28 VCM MIC 1 mg/ml (Table 24) DRPM MEPM MIC 90 4 mg/ml CLDM 3) Bacteroides fragilis B. fragilis 42 CBPs MIC 90 2 mg/ml 4 mg/ml MIC 64 mg/ml (Table 25) CEPs MIC m g/ml FMOX LMOX MIC 50 4 mg/ml
18 448 ( 62 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec Table 25. Susceptibility distribution of 42 clinical isolates of Bacteroides fragilis. Table 26. Susceptibility distribution of 39 clinical isolates of miscellaneous members of the Bacteroides fragilis group*. CLDM 64 mg/ml MIC 12 4) B. fragilis group Bacteroides thetaiotaomicron 20 Bacteroides vulgatus 7 Bacteroides eggerthii 4 Bacteroides distasonis 3 Bacteroides uniformis 3 Bacteroides caccae 1 Bacteroides merdae 1 Table 26 B. fragilis CBPs MIC 90 2 mg/ml MIC 8 mg/ml MIC 16 mg/ml CEPs MIC mg/ml CLDM 23 (59.0%) 5) Prevotella Prevotella bivia 10 Prevotella intermedia 8 Prevotella melaninogenica 8 Prevotella buccae 5 Prevotella loescheii 2 Prevotella denticola 1 Prevotella disiens 1
19 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 63 ) Table 27. Susceptibility distribution of 35 clinical isolates of Prevotella spp*. Table 27 CBPs MIC 0.5 mg/ml CBPs BLs b S. aureus MRSA 53.0% % (Fig. 1) 20) 21) 10 MRSA 50 70% 22 24) 30 40% 59.0% 29.3% MRSA 20) 30% MRSA VCM QPR/DPR ST MRSA ABK MRSA MIC 90 4 m g/ml 2 mg/ml MIC LZD 4 mg/ml MIC MSSA 84% MRSA 37% Enterococcus S. aureus VCM 2002 VCM MRSA 25,26) VCM ST MRSA MSSA MRSA MIC mg/ml 27, 28) S. epidermidis methicillin
20 450 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec % S. aureus S. haemolyticus methicillin 90% CNS TEIC ST VCM LZD QPR/DPR CNS TEIC VCM 29 31) CLSI PCG MIC m g/ml S. pneumoniae PISP PRSP % 43.4% 38.6% 46.8% 57.8% 50.9% 59.5% 53.7% 56.2% 50% 2000 PCG PBP1a 2b 2x 3 PBP 1 80% (Fig. 2) PBP PCG gpssp gpisp gprsp PCG MIC m g/ml (Table 15) 3 PBP 1 2 gpisp PCG MIC PSSP gprsp PCG PCG 1 PBP BLs PBP BLs ) BLs gprsp 21) PCG MIC 8 mg/ml PCG MIC 8 mg/ml PBP PCG BLs PBP Streptococcus BLs S. mitis group S. sanguinis group S. mitis group S. sanguinis group S. pneumoniae PBP1a 2x 2b BLs SÁNCHEZ 32) NAKAYAMA 33) PBP ABPC MIC CLSI 0.5 mg/ml PBP PISP PRSP PBP PBP 34) S. agalactiae BLs 1 S. agalactiae BLs CLSI 35) PBP2x BLs S. agalactiae B
21 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 65 ) E. faecalis ) ABPC 2000 ABPC MIC 12.5 mg/ml E. faecalis 3 (2.4%) ABPC E. faecalis ABPC PBP4 b-lactamase 37 39) VCM VCM E. casseliflavus E. gallinarum VCM 40) 41) VCM LZD vancomycin-resistant Enterococcus (VRE) E. faecalis MIC mg/ml 4 mg/ml E. gallinarum 10% QPR/DPR E. faecium 2004 ( 24%) E. faecium Enterococcus 80% QPR/DPR FEDLER % 42) Enterococcus VCM TEIC VRE 43 45) CBPs C. difficile Bacteroides MIC 8 mg/ml B. fragilis metallo b-lactamase cfia insertion sequence CBPs SóKI 46) Bacteroides cepa cfxa b-lactamase cfxa Prevotella 47) Capnocytophaga 48) b-lactamase CBPs C. difficile PELÁEZ VCM MIC 8 mg/ml 16 mg/ml 49) VCM MIC 1 mg/ml 1992 PK/PD
22 452 ( 66 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec ) 43: 12 26, ) : , ) : , ) : , ) : , ) : , ) : , ) : , ) : , ) : , ) : , ) : , ) : , ) MURRAY, P. R.; E. J. BARON, J. M. JORGENSEN, et al.: Manual of Clinical Microbiology, 8th ed. American Society for Microbiology, Washington, DC, ) Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement, M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA, ) Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 6th ed., M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, ) National Committee for Clinical Laboratory Standards: Methods for antimicrobial susceptibility testing of anaerobic bacteria. Ap-
23 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 67 ) proved standard. 7th ed., M11-A7. National Committee for Clinical Laboratory Standards, Wayne, PA, ) (1989 ) MIC ( ) Chemotherapy 38: , ) UBUKATA, K.; T. MURAKI, A. IGARASHI, et al.: Working group for penicillin-resistant S. pneumoniae: Identification of penicillin and other beta-lactam resistance in Streptococcus pneumoniae by polymerase chain reaction. J. Infect. Chemother. 3: , ) (2005 ) Jpn. J. Antibiotics 61: , ) NIKI, Y.; H. HANAKI, T. MATSUMOTO, et al.: Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens antibacterial susceptibility. J. Infect. Chemother. 15: , ) KOHLENBERG, A.; F. SCHWAB, C. GEFFERS, et al.: Time-trends for Gram-negative and multidrug-resistant Gram-positive bacteria associated with nosocomial infections in German intensive care units between 2000 and Clin. Microbiol. Infect. 14: 93 96, ) SADER, H. S.; R. MALLICK, A. KUZNIK, et al.: Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Int. J. Antimicrob. Agents 30: , ) MOET, G. J.; R. N. JONES, D. J. BIEDENBACH, et al.: Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SEN- TRY Antimicrobial Surveillance Program ( ). Diagn. Microbiol. Infect. Dis. 57: 7 13, ) DAWN, M. S.; T. R. JAMES, B. P. JEAN, et al.: Vancomycin-resistant Staphylococcus aureus in the United States, Clin. Infect. Dis. 46: , ) SAHA, B.; A. K. SINGH, A. GHOSH, et al.: Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J. Med. Microbiol. 57: 72 79, ) ZHANEL, G. G.; M. DECORBY, N. LAING, et al.: Antimicrobial-resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study, Antimicrob. Agents Chemother. 52: , ) TILLOTSON, G. S.; D. C. DRAGHI, D. F. SAHM, et al.: Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States : laboratorybased surveillance study. J. Antimicrob. Chemother. 62: , ) 2008 meropenem Jpn. J. Antibiotics 62: , ) Meropenem 2006 Jpn. J. Antibiotics 60: , ) BIEDENBACH, D. J.; J. M. BELL, H. S. SADER, T. R. FRITSCHE, et al.: Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SEN- TRY Program Report ( ). Int. J. Antimicrob. Agents 30: , ) SÁNCHEZ, M.; M. F. VICENTE, E. CERCENADO, et al.: Diversity among clinical isolates of penicillin-resistant Streptococcus mitis: indication for a PBP1-dependent way to reach high level of penicillin resistance. Int. Microbiol. 4: , ) NAKAYAMA, A. & A. TAKAO: Beta-lactam re-
24 454 ( 68 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec sistance in Streptococcus mitis isolated from saliva of healthy subjects. J. Infect. Chemother. 9: , ) FANG, C.; N. OLIVER, B. CARINA, I. MARGARET, et al.: Crossing the barrier: evolution and spread of a major class of mosaic pbp2x in Streptococcus pneumoniae, S. mitis and S. oralis. Int. J. Med. Microbiol. 297: , ) KIMURA, S.; S. SUZUKI & Y. ARAKAWA: First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52: , ) Jpn. J. Antibiotics 56: , ) ONO, S.; T. MURATANI & T. MATSUMOTO: Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob. Agents Chemother. 49: , ) ROBERTA, F.; L. MARCO, P. FABRIZIA & S. GIUSEPPE: Intrinsic penicillin resistance in enterococci. Microb. Drug Resist. 2: , ) MURRAY, B. E.: Beta-lactamase-producing enterococci. Antimicrob. Agents Chemother. 36: , ) Jpn. J. Antibiotics 61: , ) 2006 Jpn. J Antibiotics 61: , ) FEDLER, K. A.; D. J. BIEDENBACH & R. N. JONES: Assessment of pathogen frequency and resistance patterns among pediatric patient isolates. Report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn. Microbiol. Infect. Dis. 56: , ) HELIO, S. S,; A. W. AMY, R. F. THOMAS, et al.: Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect. Dis. 18: 1 9, ) SAM, K. B.; R. I. JONATHAN, B. TIMOTHY, et al.: Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58: , ) MICHAEL, J. D. & H. P. CHOONG: Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: Results from the tigecycline evaluation and surveillance trial (TEST) 2005 to Clin. Ther. 30: , ) SÓKI, J.; R. EDWARDS, M. HEDBERG, et al.: Examination of cfia-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int. J. Antimicrob. Agents 28: , ) CHANTAL, G. M.; M. ISABELLE & F. THIERRY: Sequence analysis of cfxa2-like beta-lactamases in Prevotella species. J. Antimicrob. Chemother. 51: , ) ANNE, J. G.; T. S. ZOHREH, D. LAURENT, et al.: Genetic analysis of an ambler class A extended-spectrum beta-lactamase from Capnocytophaga ochracea. J. Clin. Microbiol. 42: , ) PELÁEZ, T.; L. ALCALÁ, R. ALONSO, et al.: Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46: , 2002
25 Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 69 ) Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006 TAKAHIRO YAMAGUCHI 1), ISAMU YOSHIDA 1), YOSHIHISA ITOH 2), MINEJI TACHIBANA 2), CHOICHIRO TAKAHASHI 3), MITSUO KAKU 4), KEIJI KANEMITSU 4,5), MASAHIKO OKADA 6), YOSHINORI HORIKAWA 6), JOJI SHIOTANI 7), HIROYOSHI KINO 8), YUKA ONO 8), HISASHI BABA 9), SHUJI MATSUO 10), SEISHI ASARI 11), MASAHIRO TOYOKAWA 11), KIMIKO MATSUOKA 12), NOBUCHIKA KUSANO 13), MOTOKO NOSE 13), MITSUHARU MURASE 14), HITOSHI MIYAMOTO 14), TETSUNORI SAIKAWA 15), KAZUFUMI HIRAMATSU 15), SHIGERU KOHNO 16), KATSUNORI YANAGIHARA 16), NOBUHISA YAMANE 17), ISAMU NAKASONE 17), HIDEKI MAKI 1) and YOSHINORI YAMANO 1) 1) Developmental Research Laboratories, Shionogi & Co., Ltd., Futaba-cho, Toyonaka, Osaka , Japan 2) Asahikawa Medical College Hospital 3) Yamagata University Hospital 4) Tohoku University Hospital 5) Fukushima Medical University Hospital 6) Niigata University Medical & Dental Hospital 7) Cancer Institute Hospital 8) Mitsui Memorial Hospital 9) Nagoya University Hospital 10) Tenri Hospital 11) Osaka University Hospital 12) Osaka General Medical Center 13) Okayama University Hospital 14) Ehime University Hospital 15) Oita University Hospital 16) Nagasaki University Hospital 17) University Hospital of the Ryukyus The activity of antibacterial agents against aerobic Gram-positive cocci (26 species, 1022 strains) and anaerobic bacteria (23 species, 184 strains) isolated from clinical specimens in 2006 at 16 clinical facilities in Japan were studied using either broth microdilution or agar dilution method. The ratio of methicillin-resistant strains among Staphylococcus aureus and Staphylococcus epidermidis was 53.0% and 65.8%, suggesting that resistant strains were isolated at high frequency. Vancomycin (VCM) and quinupristin/dalfopristin (QPR/DPR) had good antibacterial activity against methicillin-resistant S. aureus and methicillin-resistant S. epidermidis, with MIC 90 s of 2 mg/ml. The ratio of penicillin (PC) intermediate and resistant strains classified by mutations of PC-binding proteins among Streptococcus pneumoniae was 87.6%. Ceftriaxone, cefpirome, cefepime, car-
26 456 ( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 6 Dec bapenem antibiotics, VCM, teicoplanin, linezolid(lzd) and QPR/DPR had MIC 90 s of 1 mg/ml against PC-intermediate and resistant S. pneumoniae strains. Against all strains of Enterococcus faecalis and Enterococcus faecium, the MICs of VCM and TEIC were under 2 mg/ml, and no resistant strain was detected, suggesting that these agents had excellent activities against these species. 10.9% of E. faecalis strains or 3.5% of E. faecium strains showed intermediate or resistant to LZD. 24.4% of E. faecium strains showed intermediate or resistant to QPR/DPR. Against all strains of Clostridium difficile, the MIC of VCM were under 1 mg/ml, suggesting that VCM had excellent activity against C. difficile. Carbapenems showed good activity against Peptococcaceae, Bacteroides spp., and Prevotella spp. However since several strains of Bacteroides fragilis showed resistant to carbapenems and the susceptibility of this species should be well-focused in the future.
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
More information日本化学療法学会雑誌第51巻第4号
000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More informationTable 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More information02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
More information70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
More informationStreptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
More information03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
More information日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
More informationVOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More information172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
More informationVOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
More informationApr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
Apr. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 12 105 ( 13 ) 2008 NTT 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr. 2010 JA 2010 1 27 1982 7 2008 2008 4 2009 3 1 215 173 (80.5%) 694 18 357
More information日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More informationCHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More informationAug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More information2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More informationTable 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
More information(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
More information日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
More informationR06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
More informationCHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
More informationCHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
More informationOct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
More informationTable 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
More information49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e
Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC
More information1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
More informationDIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
More information2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon
Feb. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 1 1 2008 2009 2011 10 25 2008 6 2009 4 Streptococcus pneumoniae 377 penicillin-binding protein: PBP 2004 S. pneumoniae 160 2 2 THE JAPANESE JOURNAL OF
More informationCHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More informationPCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
More informationFeb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
More informationFig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
More informationFeb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
More informationCHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
More information日本化学療法学会雑誌第53巻第S-1号
Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More informationKey words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin Table 1 Differentiation of group D streptococcia aderived from R.R.Facklam1,2),K.C.Gross-et al3),and
More informationCHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
More informationCHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationb) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
More informationCHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More information600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN
More informationFig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
More informationE Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
More informationVOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationTable 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationCHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More information_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
More information2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
More informationVOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
More informationNationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc
J Infect Chemother (2012) 18:609 620 DOI 10.1007/s10156-012-0434-3 SURVEILLANCE Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More information43 Acontum apoiense 17 19581147 1988 17 2001 A4 A4 H17. 4.20. 3. 1012 131421 IT 50 10,340 11,521 2 3 8 9 9 10 10 15 19 20 21 21 1617 22 23 1904 1928 1940 Nature MRSA MRCNS VREVRSA PRSP BRNAR MDRP ESBL)MBL
More informationCHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)
346 ( 78) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 2007 72 12,919 NTT THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 347 ( 79) 348 ( 80) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 THE JAPANESE JOURNAL OF
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
More information日本化学療法学会雑誌第50巻第6号
13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationGenus Corynebacteria Non-lipophilic The nonlipophilic bacteria may be classified as fermentative and non-fermentative: Fermentative Corynebacteria Cor
Corynebacterium kroppenstedtii Genus Corynebacteria Non-lipophilic The nonlipophilic bacteria may be classified as fermentative and non-fermentative: Fermentative Corynebacteria Corynebacterium diphtheriae
More informationVOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
More informationuntitled
111-245010-N-04 21300AMY00327000 20116 2 20099 1 BD BBLCRYSTAL ANR BD BBLCRYSTAL ANR 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationVOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
More informationCHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur
CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella
More informationCHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
More information日本化学療法学会雑誌第59巻第6号
P P Streptococcus pneumoniae S. pneumoniae Key words Streptococcus pneumoniae Fig. 1. Capsular swelling reaction of S. pneumoniae type 6B. Cells are stained dark blue using a methylene blue. Capsule is
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More information概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
More informationR01
1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200
More informationTable 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
More informationCHEMOTHERAPY 34 T-2588の APR.1986 嫌 気 性 菌 に 対す る抗 菌 作 用 に つ い て 沢 赫 代 神 野 英 毅 青 木 誠 小 林 と よ子 渡 辺 邦 友 上 野 一 恵 岐阜大学医学部附属嫌気性菌実験施設 新 し く 開 発 さ れ た 経 口 用 エ ス テ ル 型 セ フ ェ ム 系 抗 生 剤T-2588の 口 剤 で あ るcephalexin(CEX),cefaclor(CCL)
More information日本 化 学療 法 学 会 雑 誌 262 JULY 血 球 数8,700/μl,CRP (症例2) 64歳 の男 性 1980年 ご ろ よ り慢 性 肺 気 腫 と診 断 さ れ て い る 本症 例 は まず1993年 に 喀 痰 細 胞 診Class皿 と 認 め られ た が,こ 5.0m
VOL.46 NO.7 Eikenella corrodens Key words: Eikenella corrodens, 日本 化 学療 法 学 会 雑 誌 262 JULY 血 球 数8,700/μl,CRP (症例2) 64歳 の男 性 1980年 ご ろ よ り慢 性 肺 気 腫 と診 断 さ れ て い る 本症 例 は まず1993年 に 喀 痰 細 胞 診Class皿 と 認 め
More informationFeb THE JAPANESE JOURNAL OF ANTIBIOTICS ,4 2,4 2,4 2,3,4 2,3,4 2,3, ,3, Garenoxacin GRNX Levofloxacin LV
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 27 27 1,4 2,4 2,4 2,3,4 2,3,4 2,3,4 2 1 2,3,4 1 2 3 4 2015 10 21 9 Garenoxacin GRNX Levofloxacin LVFX Sitafloxacin STFX Moxifloxacin MFLX Pharmacokinetics-Pharmacodynamics
More information